Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway

Impact · against what's priced in

The updates on the CUT-less and MRD trials are mildly positive as they outline potential pathways to expand Hexvix's clinical utility and market penetration. However, because these are 'trials in progress' without final data, they provide no immediate catalyst for a valuation change.

PHO+0.20

No priced-in read yet